Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practicing in specific cardiology domains.
The use of diuretics (and beta-blockers) to treat hypertension has known a dramatic decline since the early 1980’s through to the early 1990s with the introduction of ACE-inhibitors and calcium channel blockers. However, thiazide diuretics are still a first line option to treat arterial hypertension, due to their efficacy and cost-effectiveness profile. We have presented major trials on this subject in this review.
Thiazide Diuretics have been used since the late fifties in the treatment of hypertension and remain one of the most important group of drugs used to reduce blood pressure, due to their efficacy and cost-effectiveness profile. The use of diuretics (and beta-blockers) to treat hypertension has known a dramatic decline since the early 1980’s through to the early 1990s with the introduction of ACE-inhibitors and calcium channel blockers. Thiazides were used in much higher doses then and concerns were raised regarding their metabolic effects (1). Nevertheless, in this review we will try to demonstrate that thiazide diuretics are still a first line option to treat arterial hypertension.
The onset of action occurs after 2 to 3 hours for most thiazides, with little natriuretic effect occuring beyond 6 hours (2). The bioavailability and plasma half-lives explain the differences in pharmacokinetics of different compounds, and hydrochlorothiazide (HCTZ), which has the best profile, was elected as the paradigm of thiazides for the treatment of hypertension. Its half-life of 8 to 12 hours permits effective once daily doses. Among thiazides,
Thiazides can reduce the excretion of calcium and uric acid and therefore increase their plasma levels. As well, they increase potassium and magnesium excretion, leading to hypokalemia and hypomagnesemia. Hypokalemia seems to be implicated in the pathogenesis of thiazide-induced dysglycemia. We will come to this topic later in this paper. New onset diabetes has been reported in patients receiving thiazides. According to Carter et al (7) the use of thiazides over several years may lead to an excess of 3 to 4% of new cases of diabetes.
Most major clinical trials used either HCTZ or chlorthalidone. The trial sponsored by the National Heart, Lung and Blood Institute (ALLHAT) used chlorthalidone on the belief that it might have advantages related to its longer duration of action. In addition, the data from Multiple Risk Factor Intervention Trial (MRFIT) suggested that chlorthalidone could confer mortality benefits over HCTZ. When MRFIT was begun, either chlorthalidone or HCTZ could be used according to the experience of each clinical centre. After 7 years the Policy Advisory Board recommended that all subjects be given chlorthalidone because the trend of mortality was unfavourable in the 9 clinics using HCTZ compared to the favourable trend in the 6 clinics using chlorthalidone (8). In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), conducted between 1994 and 2002, chlorthalidone was chosen to be compared with a calcium channel blocker (CCB-amlodipine) and an ACE-inhibitor (lisinopril). Results, after a mean follow-up of 4, 9 years, showed that a thiazide –type diuretic was superior in preventing major forms of cardiovascular disease (9). Carter and co-workers on a literature search from 1960 to 2003 evaluated the pharmacokinetic and blood pressure lowering effects of both drugs. They found that chlorthalidone is 1.5 to 2.0 times as potent as HCTZ, and a much longer duration of action (3). A more recent paper of the same group (10) compares the antihypertensive effects of both drugs appealing to ambulatory and office blood pressure. The results show that chlorthalidone is more effective in lowering systolic blood pressure measurements than HCTZ, as evidenced by ambulatory BPs, due primarily to the reduction of night time systolic BP. This differences were not apparent with office BP.
There is a consensus that large randomized trials measuring fatal and non-fatal events represent the strongest type of evidence available (11) ALLHAT was designed to address the issue of which class of drugs should be the first –step therapy for hypertension. In the early 90s, that was a very timely question due to the recent introduction of new groups of drugs for hypertension. The overall findings of the trial showed that CHD risk was not improved for any of the newer agents compared with the diuretic treatment represented by chlorthalidone, and that total mortality was also similar for the 4 groups (9). However, diuretic based therapy was superior to CCB, ACE-inhibitor and alfa-blocker in preventing 1 or more major forms of CVD, including heart failure and, in some cases, stroke. The observed rates of heart failure were higher with amlodipine and lisinopril than with chlorthalidone. Some authors suggest that the longer duration of action of chlorthalidone may explain the advantage in CVD prevention over HCTZ.
The Second Australian National Blood Pressure Study (ANBP2) compares diuretic-based (HCTZ) with ACE-inhibitor-based (enalapril) antihypertensive treatment. A total of 6083 participants, aged 65 to 84 years, were followed for 4 years (11). The results favoured the ACE-inhibitor group, with a decrease in cardiovascular events and myocardial infarction, and a equal number of strokes, despite a similar reduction of blood pressure. The results of ANBP2 were published less than 1 year after ALLHAT and left the medical community confused such that Frohlich asked in an editorial (12): What are we to believe? In his comment he emphasised the difference between the study drugs: ANBP2 used HCTZ as the diuretic, whereas ALLHAT used chlorthalidone. The two trials used vastly different definitions of primary and secondary outcomes. The characteristics of the two populations were different with 35% of blacks in ALLHAT and only 5% in ANBP2. He concludes that the 2 studies are not comparable, and that the choice of appropriate therapy should me made according to the specific problems of the patient. At the same time an important meta-analysis, using a new methodology, network meta-analysis, which combines direct and indirect evidence to better define risks or benefits, was presented by Psaty et al (13). Data were combined from 42 clinical trials that included more than 190,000 patients randomised to 7 major treatment strategies, including placebo. For all outcomes low-dose diuretics were superior to placebo: CAD; congestive HF; stroke; CVD events; CV mortality. None of the first-line treatment strategies – beta-blockers, ACE-inhibitors, CCB, alfa-blockers and angiotensin receptor blockers (ARB) – was significantly better than low-dose diuretics for any outcome. The authors conclude that low-dose diuretics are the most effective first-line treatment for preventing cardiovascular disease morbidity and mortality.
Recent epidemic of obesity and diabetes raised again the problem of adverse effect of thiazides, namely the metabolic effects. In the ALLHAT, among the patients without diabetes mellitus (DM) at baseline, the percentage of incident DM was 11% in the chlorthalidone group, 9.3% in the amlodipine group and 7.8% in the lisinopril group, respectively. In spite of that higher incidence of DM with the thiazide it did not translate into any disadvantage for the diuretic arm during the mean follow-up of 4.9 years (1). In a recent network meta-analysis Elliot and Meyer (14) undertook a systematic review up to Sept 2006 and identified 22 clinical trials with more than 143,000 participants without DM at randomization. The main outcome was the proportion of patients who developed DM. The odds ratio for incident DM was, with ARBs and Ace-inhibitors, inferior to placebo; it was superior with CCBs(1.05), beta-blockers(1.25) and diuretics(1.34) p=0.001. The authors conclude that the association of antihypertensive drugs with incident DM is lowest for ARB and ACE-inhibitors followed by CCB, placebo, beta-blockers and diuretics in rank order. However, it must be recognized that in a typical hypertensive population the great majority of incident DM that occurs while taking a thiazide is not drug induced but is due to typical causes of type 2 diabetes.
From ALLHAT data regarding incident DM at 4 years, its fraction can be estimated as 83% (1). Messerli et al (15) in his controversy with Cutler and Davis (Circulation, May 20,2008) accepts that new onset diabetes (NOD) associated with diuretics may be reversible on the discontinuation of the diuretic. Thus treatment withdrawal could potentially separate the drug induced NOD from spontaneously occurring NOD (15). The evidence on whether the development of dysglycemia with any antihypertensive drug treatment produces adverse CV effects is mixed (14). Both ALLHAT and SHEP (Systolic Hypertension in the elderly Program) (16), the largest and longest follow-up studies, show no significant adverse CV events from new diuretic-associated diabetes. In ALLHAT diuretic-based therapy still afforded major CV benefits compared with amlodipine and lisinopril, even in patients with diabetes. Overall there was no consistent evidence from observational studies that thiazide diuretics increased the risk of DM among hypertensive patients (7).
The difficulty in establishing a clinical connection between diuretic treatment and NOD is the absence of a link between diuretics and hyperglycemia. Zillich et al (17) conducted a literature search from 1966 to 2004 to identify clinical trials using thiazides where the metabolic effect on potassium and glucose are reported. The data collected from 59 clinical trials establish a correlation coefficient of 0,54 (P<0.01) thus suggesting that thiazide-induced hypokalemia is associated with increased blood glucose. Experimental work indicate that low plasma potassium could impair insulin secretion and thereby increase plasma glucose (18). Treatment of thiazide induced hypokalemia may reverse glucose intolerance and prevent diabetes (17). Hypokalemia can be prevented or treated with K+ supplements or combinations of thiazides with K+ sparing diuretics (amiloride and triamterene) and aldosterone-receptor antagonists (eplerenone or spironolactone). On the other hand it has been known, for many years, that when an ACE-inhibitor is added to a thiazide, the metabolic effects of the diuretic are minimized. In all, the cause of diabetes epidemic is increasing overweight/obesity and physical inactivity. Most NOD in diuretic treated patients is not diuretic induced. Cases can likely be prevented by avoiding significant potassium depletion – Cutler and Davis (1).( Controversy with Messerli et al – Circulation, May 20, 2008).
In the ACCOMPLISH trial (19) (Avoiding CV events through combination therapy in patients living with systolic hypertension) 11,506 patients with hypertension who were at high risk for CV events, were randomised to receive treatment with either benazepril plus amlodipine or benazepril plus HCTZ. The hypothesis to test was if the association of a ACE-inhibitor plus a CCB would be better in reducing CV events than ACE-inhibitor plus a thiazide diuretic. The trial was prematurely terminated after a mean follow-up of 36 months, when the boundary of the prespecified stopping rule was exceeded. There were 552 primary-outcome events in the benazepril-amlodipine group (9.6%) and 679 in the benazepril-HCTZ group (11.8 %), representing a relative risk reduction of 19.6% (P<0.001). The authors concluded that Ace-inhibitor+CCB was superior to ACE-inhibitor+HCTZ in reducing CV events in patients with hypertension who were at high risk for such events. More recently the results of renal outcome have showed that benazepril +amlodipine slows the progression of nephropathy to a greater extent (20). In the editorial by Chobanian(21) the use of HCTZ instead of chlorthalidone as diuretic is emphasized and the authors considered that the dose of HCTZ used (averaging 19mg/day) could not provide 24 hours BP control. The experimental evidence that ACE-inhibitors and CCB have vasoprotective effects may be important, as well. This property is not shared by diuretics, but its clinical relevance is uncertain. Finally Chobanian stresses that the most important treatment issue is to reduce BP to goal levels. How this is achieved is less important. The preference for diuretics in the management of hypertension has been challenged in light of the results of the ACCOMPLISH Trial. The notion that newer agents have beneficial blood pressure-independent effects has been the basis of their marketing. This cardioprotective or vasoprotective effects has been also mentioned to explain the effects of ramipril in the HOPE trial (22). We know, today, that the reduction of blood pressure “per se” explains the main benefits in terms of CV morbidity and mortality. The best explanation for the paradoxical results of ALLHAT and ACCOMPLISH trials is the use of different diuretics – Chlorthalidone and HCTZ, respectively (23). The results of 10 years follow-up of the ALLHAT population, presented at the American Heart Association Meeting, November, 2009, showed that amlodipine and lisinopril treatments were not superior to Chlorthalidone-based treatment in preventing major CV events (24). In a recent (2009) reappraisal of European guidelines on hypertension management (25), a European Society of Hypertension statement, confirms that major antihypertensive drug classes do not differ significantly for their overall ability to reduce BP in hypertension. They also emphasize that cardiovascular protection by antihypertensive treatment substantially depends on BP lowering per se, regardless of how it is obtained. These two points are also the conclusions of a meta-analysis by Law and co-workers from the London School of Medicine (26). Their analysis included 147 randomised clinical trials published between 1966 and 2007 and the conclusion is categoric: “ All the classes of BP lowering drugs have a similar effect in reducing CHD events and stroke for a given reduction in BP, so excluding material pleiotropic effects” In CONCLUSION we can cite Norman Kaplan in a recent editorial in “Hypertension”, November 2009: “ Appropriate use of diuretics can still be a safe and effective way to treat hypertension” (27).
Table 1. Thiazides in hypertension - CLINICAL PHARMACOLOGY
1. The onset of action occurs after 2 to 3 hours for most thiazides.
2. Most Thiazides have a half-life of 8 to 12 hours, just permiting effective once daily dosing
3. Chlorthalidone has an elimination half-life of 50 t0 60 hours, and is twice as potent as hydrochlorothiazide.
4. Initial decreases in blood pressure are attributed to the reductions in extracellular fluid and plasma volumes. The persistent antihypertensive effects are due to an overall reduction in systemic resistance.
Table 2. Thiazide in hypertension- ADVERSE EFFECTS
3. Dysglycemia. Diabetes
Table 3. Thiazides in hypertension - ALLHAT vs ACCOMPLISH
1. The preference for diuretics in the management of hypertension has been challenged in light of the results of the ACCOMPLISH Trial.
2. The best explanation for the paradoxical results of ALLHAT and ACCOMPLISH trials is the use of different diuretics – Hydrochlorothiazide and chlorthalidone.
3. The ALLHAT trial demonstrated, for the first time, the superiority of chlorthalidone over ACE-inhibitors and Calcium Channel Blockers in patients with Diabetes and Chronic Renal Disease.
4. Chlorthaldone is more potent and has a longer duration of action than hydrochlorothiazide, and should be preferred, alone or in combination, for the management of hypertension.
Adapted from Fuchs FD, ref.23
Table 4. Thiazides in hypertension - CHOICE OF ANTIHYPERTENSIVE DRUGS
1. The main benefits of antihypertensive therapy are due to lowering of blood pressure, per se, regardless of how it is obtained.
2. Major antihypertensive drugs classes do not differ significantly for their ability to reduce blood pressure
3. Each drug class has contra-indications as well as favourable effects in specific clinical settings. The choice of drugs should be made according to this evidence.
1. Cutler JA, Davis BR. Thiazyde-Type Diuretics and Beta-adrenergic Blockers as first-line Drug treatments for Hypertension. Circulation 2008;117:2691-2705. 2. Ernst MH, Moser M. Use of Diuretics in Patients with Hypertension. N Engl J Med 2009;361:2153-64 3. Robinson DM, Wellington K. Indapamide Sustained Release. A review of its use in the treatment of hypertension. Drugs 2006; 66:257-71 4. Gosse P, Sheridan DJ, Zannad F, et al. Regression of LV hypertrophy in hypertensive patients treated with indapamide SR 1.5mg versus enalapril 20mg: The LIVE study.J Hypertens 2000;18: 1465-75. 5. London GM, Schmieder R, Calvo C, et al. On behalf of the X-CELLENT Study Investigators. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study. Am J Hypertens 2006;19:113-21 6. Marre M, Garcia Puig J, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The Nestor Study. J Hypertens 2004;22:1613-22. 7. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus Chlorthalidone. Hypertension 2004;43:4-9 8. Multiple Risk Factor Intervention Trial Research Group. Mortality after 10 ½ years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 1990;82:1616-28. 9. The ALLHAT Officers and Coordinators. Major Outcomes in High- Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. JAMA 2002;288:2981-97. 10. Ernst ME, Carter BL, Goerdt ChJ, et al. Comparative antihypertensive effects of Hydrochlorothiazide and Chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352-8. 11. Wing LMH, Reid ChM, Ryan Ph, et al. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92. 12. Frohlich ED. Treating Hypertension – What are we to believe?. N Engl J Med 2003;348:639-41. 13. Psaty BM, Lumley Th, Furberg CD, et al. Health outcomes associated with various antihypertensive Therapies used as first-line agents. A network meta-analysis. JAMA 2003;289:2534-44. 14. Elliott WJ, Meyer PM. Incident Diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-7. 15. Messerli FH, Bangalore S, Julius S. Risk/Benefit Assessment of beta-blockers and Diuretics Precludes their use for first-line Therapy in Hypertension. Circulation 2008;117:2706-15. 16. SHEP Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons with Isolated Systolic Hypertension. JAMA1991;265:3255-64. 17. Zillich AJ, Garg J, Basu S, et al. Thiazide Diuretics, Potassium and the development of Diabetes. A quantitative review. Hypertension 2006;48:219-24. 18. Carter BL, Einhorn PT, Brands M, et al. Thiazide-induced Dysglycemia. Call for research from a working group from the National Heart, Lung and Blood Institute. Hypertension 2008; 52:30-6. 19. Jamerson K, Weber MA, Bakris GL, et al. for the ACCOMPLISH trial investigators. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. N Engl J Med 2008;359: 2417-28. 20. Bakris GL, Sarafidis PA, Weir MR, et al. For the ACCOMPLISH trial investigators. Renal outcome with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH) : a prespecified secondary analysis of a randomized controlled trial. Lancet, 18/Feb/2010. e-on line publication. 21. Chobanian AV. Does it matter how hypertension is controlled? N Engl J Med 2008;359:2485-88. 22. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzime inhibitor, Ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342: 145. 23. Fuchs FD. Diuretics: still essential drugs for the management of hypertension. Expert Rev Cardiovasc Ther 2009;7:591-8. 24. Cushman WC. On behalf of the ALLHAT Collaborative research group. Ten years follow-up . Presented at the AHA, Orlando, Nov. 2009 25. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force Document. J Hypertens 2009;27:2121-58. 26. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomized trials in the context of expectations from prospectiveepidemiological studies. BMJ 2009;338:1665 27. Kaplan NM. The choice of thiazide Diuretics. Why Chlorthalidone may replace Hydrochlorothiazide. Hypertension 2009;54:
Rafael Ferreira, M.D., Ph D, FESC Professor of Cardiology, Lisbon University
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved